Abstract

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4

Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C

Issue: Jul/Aug 2020 - Volume 24, Number 4

Page(s): 327-336

Download in electronic PDF format for $75
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 1
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 2
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 3
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 4
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 5
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 6
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 7
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 8
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 9
  • Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Page 10

Note: Electronic version includes errata or revisions.

Abstract

Extemporaneous compounding in veterinary practice sometimes represents the only possibility for treating animals in the absence of appropriate commercial formulations, especially for particular species. This method involves manipulating pharmaceutical active ingredients to a suitable dosage and formulation for administration to humans or animals. However, veterinarians and pharmacists should focus on the risk of potential incompatibilities and instability of their preparations. To help practitioners in drug compounding, we investigated the stability of oral suspensions of tramadol, fluoxetine, and doxycycline in a commercial ready-to-use vehicle (SyrSpend). A validated high-performance liquid chromatography method was developed to assay these active pharmaceutical ingredients. The oral suspensions were prepared at two concentration ranges and were stored in amber glass bottles under refrigerated conditions and at room temperature. After 90 days, the average recovery rates were between 90% and 110% for tramadol (5 mg/mL to 30 mg/mL) and doxycycline  (2 mg/mL to 10 mg/mL) without organoleptic modification. For fluoxetine, only the formulation at 2 mg/mL was stable; at higher concentrations, the uniformity of the suspension was compromised.

Related Keywords

  • B. Espana
  • tramadol
  • fluoxetine
  • doxycycline
  • oral suspensions
  • veterinary compounding
  • pain relief
  • behavioral disorders
  • anxiety disorders
  • antibiotic
  • antimicrobial agents
  • compatibility
  • physical stability
  • chemical stability
  • dogs
  • canines
  • cats
  • felines
  • bioavailability

Related Categories

  • MENTAL HEALTH
  • PAIN MANAGEMENT
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • VETERINARY
  • INFECTIOUS DISEASE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
May/Jun 2023
Pg. 234
Doxycycline 166.7-mg/mL Oral Suspension (Veterinary)
Author(s): Allen Loyd V Jr
Nov/Dec 2006
Pg. 418
Case Report: Transdermal Fluoxetine as Therapy for Feline Anxiety
Author(s): Fields Shannon W
Jul/Aug 2020
Pg. 321
Tramadol Hydrochloride 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
May/Jun 2017
Pg. 242-246
Absorption of Transdermal Fluoxetine Compounded in a Lipoderm Base Compared to Oral Fluoxetine in Client-owned Cats
Author(s): Eichstadt Lauren R, Corriveau Lorraine A, Moore George E, Knipp Gregory T, Cooper Bruce R, Gwin Wilson E
Sep/Oct 2025
Pg. 409-419
Microbiological and Physical Stability of Extemporaneous Oral Suspensions Compounded with SyrSpend® SF PH4
Author(s): Kegele Carolina Schettino, Dijkers Eli, Polonini Hudson
Sep/Oct 2015
Pg. 428-431
Stability of Levothyroxine, Doxycycline, Hydrocortisone, and Pravastatin in Liquid Dosage Forms Stored at Two Temperatures
Author(s): Nahata Milap C
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Mar/Apr 2004
Pg. 156-159
Effect of Freezing, Long-Term Storage and Microwave Thawing on the Stability of Tramadol in 5% Dextrose Infusion in Polyvinyl Chloride Bags
Author(s): Lebrun John, Hecq Jean-Daniel, Vanbeckbergen Danielle, Jamart Jacques, Galanti Laurence M
Nov/Dec 2017
Pg. 491
Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 412
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 140
Alprazolam 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 10-14
Women's Oral Health: Is There a Hormonal Link?
Author(s): Preckshot John
May/Jun 2010
Pg. 182-192
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Author(s): Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 493
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 494
Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 492
Clonazepam 0.2 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr